Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In treatment-resistant depression, commonly defined as a lack of response to two or more consecutive treatments during the current depressive episode, the percentage of patients with remission is low and the percentage with relapse is high. The efficacy and safety of esketamine nasal spray as compared with extended-release quetiapine augmentation therapy, both in combination with ongoing treatment with a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI), in patients with treatment-resistant depression are unknown. METHODS: In an open-label, single-blind (with raters unaware of group assignments), multicenter, phase 3b, randomized, active-controlled trial, we assigned patients, in a 1:1 ratio, to receive flexible doses (according to the summary of product characteristics) of esketamine nasal spray (esketamine group) or extended-release quetiapine (quetiapine group), both in combination with an SSRI or SNRI. The primary end point was remission, defined as a score of 10 or less on the Montgomery-Åsberg Depression Rating Scale (MADRS), at week 8 (scores range from 0 to 60, with higher scores indicating more severe depression). The key secondary end point was no relapse through week 32 after remission at week 8. All patients were included in the analysis; patients who discontinued the trial treatment were considered as having had an unfavorable outcome (i.e., they were grouped with patients who did not have remission or who had a relapse). Analyses of the primary and key secondary end points were adjusted for age and number of treatment failures. RESULTS: Overall, 336 patients were assigned to the esketamine group and 340 to the quetiapine group. More patients in the esketamine group than in the quetiapine group had remission at week 8 (91 of 336 patients [27.1%] vs. 60 of 340 patients [17.6%]; P = 0.003) and had no relapse through week 32 after remission at week 8 (73 of 336 patients [21.7%] vs. 48 of 340 patients [14.1%]). Over 32 weeks of follow-up, the percentage of patients with remission, the percentage of patients with a treatment response, and the change in the MADRS score from baseline favored esketamine nasal spray. The adverse events were consistent with the established safety profiles of the trial treatments. CONCLUSIONS: In patients with treatment-resistant depression, esketamine nasal spray plus an SSRI or SNRI was superior to extended-release quetiapine plus an SSRI or SNRI with respect to remission at week 8. (Funded by Janssen EMEA; ESCAPE-TRD ClinicalTrials.gov number, NCT04338321.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The ESCAPE-TRD trial reported a comparatively smaller effect size for esketamine versus quetiapine (− 2.2 MADRS points; 95% CI, − 3.6 to − 0.8) at 32 weeks [19].”
In the citing paper
“At 8 weeks, esketamine nasal spray demonstrated superior efficacy [19].”
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
Treatment-resistant depression: therapeutic trends, challenges, and future directions
Al-harbi (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s29716 · Cited by 796
Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795
Self-citationDaly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606
Ochs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.10.008 · Cited by 481
Cited by
Items 101–200 of 218
Oliveira-Maia, A. J., Rive, B., Godinov, Y., & Mulhern-Haughey, S. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1459633 · Cited by 5
Self-citationHarding, L., Zhdanava, M., Teeple, A., Shah, A., Boonmak, P., Pilon, D., & Joshi, K. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.12.006 · Cited by 3
Wang, L., Chen, X., Gu, X., Smedt, H. D., Popova, V., Fu, D., Canuso, C. M., Drevets, W. C., & Chen, G. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s417027 · Cited by 6
“53 Notably, one outcome measure that was not compared in our meta-analysis was the remission rate.”
Self-citationLicit use of illicit drugs for treating depression: the pill and the process
Pacheco, A. T., & Moghaddam, B. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180217 · Cited by 3
“More recent clinical trials have shown a range of strong to weak to no significant effects in relieving symptoms of depression (49, 52, 53, 54).”
BackgroundQuantitative evaluation of multiple treatment regimens for treatment-resistant depression
Feng, Y., Lv, Y., Yang, J., Xu, L., Chen, J., Huang, J., Ren, J., Zheng, Q., & Li, L. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf007 · Cited by 5
Zhang, Y., Ke, Z., Luo, J., Chen, Q., Xu, X., Jiang, X., & Xiong, J. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s514640 · Cited by 5
Huang, R.-H., Lin, B., Yu, L., Luo, Q., Tian, H., Li, C., Wei, N., Zhuang, S., Chen, J., & Li, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1630158 · Cited by 2
“S-ketamine, a glutamate NMDAR antagonist, is the focus of recent attention due to its novel, fast-acting pharmacotherapies for depression (McIntyre et al., 2021; Reif et al., 2023; Daly et al., 2019).”
Canuso, C. M., Bossie, C. A., Fu, D., Lane, R., Doherty, T., Lignugaris, A., Fagiolini, A. M., Llorca, P., McIntyre, R. S., Reif, A., et al. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250250 · Cited by 2
Self-citationLi, P., & Gao, Y. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1651207 · Cited by 4
“Phase III trial results (TRANSFORM-3) revealed that intranasal esketamine combined with oral antidepressants achieved signi fi cantly higher remission rates at week 4 compared to placebo plus antidepressants (44).”
A long, strange trip: Ketamine treatment in psychiatry
Nutt, D. J., Morgan, C. J. A., Erritzøe, D., Greenway, K. T., & Young, A. H. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251379393 · Cited by 5
Self-citationApplication of esketamine during emergency care: current status and perspectives
Wan, Y., Zhang, W., Guo, X., Zhu, C., Wang, K., & Li, M. (2025) · Anesthesiology and Perioperative Science · doi:10.1007/s44254-025-00149-8 · Cited by 6
“IN administration (0.8 – 1.2 mg/kg) demonstrates a significantly lower incidence of psychiatric symptoms compared with IV delivery [23].”
InfluentialProgress, potential and pitfalls of ketamine as a treatment for depression
Orsini, D. K., Luch, S. D. D., Lovell, G. F. M., & Rosenblat, J. D. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2637587 · Cited by 2
“More recently, esketamine was compared to one of the current standard augmentation strategies, namely, add-on quetiapine in a large, phase III RCT [18].”
Wilkinson, S. T., Prashad, S., Dalthorp, R., Harding, L., Kitay, B. M., Parikh, S. V., Dziura, J. D., Clayton, A. R., Fram, G., Lepoutre, V., et al. (2026) · Contemporary Clinical Trials · doi:10.1016/j.cct.2026.108273 · Cited by 2
Baune, B., Rosemann, K., Hefter, D., Tonkul, M., & Kavakbasi, E. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-07980-8 · Cited by 2
“Head-to-head evidence further indicates superiority of esketamine plus an oral AD over quetiapine XR-based strategies for achieving acute and sustained remission in TRD (ESCAPE-TRD) [15].”
InfluentialHarding, L., Zhdanava, M., Shah, A., Pesa, J. A., Totev, T. I., Tardif‐Samson, A., Pilon, D., & Joshi, K. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2380743 · Cited by 2
Symptom management in isocitrate dehydrogenase mutant glioma
Walbert, T., Avila, E. K., Boele, F. W., Hertler, C., Lu‐Emerson, C., van der Meer, P. B., Peters, K. B., Rooney, A. G., Templer, J. W., & Koekkoek, J. A. F. (2024) · Neuro-Oncology Practice · doi:10.1093/nop/npae088 · Cited by 9
Advancing ketamine in the treatment hierarchy for refractory depression
Nigam, K. B., King, F., & Forcén, F. E. (2024) · The British Journal of Psychiatry · doi:10.1192/bjp.2024.217 · Cited by 2
“7 Despite clinical evidence supporting ketamine as an effective augmentation strategy, economic considerations present an additional barrier to increased utilisation.”
Hildebrand, F., Cukaci, C., Schoeny, H., Baumgartinger, C., Stelzer, B., Spedicato, M., Frey, T., Catani, M., Schmetterer, K. G., Frey, R., et al. (2025) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-025-05790-7 · Cited by 5
Self-citationAlborghetti, M., Lionetto, L., Lombardozzi, G., Montaguti, L., Trovini, G., Donato, D., Costanzi, G., Bernardini, D. D., Catapano, F., Surano, M., et al. (2025) · Current Neuropharmacology · doi:10.2174/011570159x356952241216172603 · Cited by 3
Zhao, G.-G., Zhao, J., Kong, Y., Pang, Y.-Y., Zheng, X., & Zhang, Y.-W. (2025) · World Journal of Psychiatry · doi:10.5498/wjp.v15.i9.109458 · Cited by 2
Marci, C. D., Joshi, K., Severtson, S. G., Breeze, J. L., & Jha, M. K. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07485-w · Cited by 2
“As an example, Reif et al. [11] found that 27% of participants treated with esketmaine achieved remission by eight weeks using the MADRS threshold.”
Beck, K., & Young, A. H. (2024) · The Canadian Journal of Psychiatry · doi:10.1177/07067437241259896 · Cited by 2
“3,4,6 This is in keeping with guidelines published more recently 3 but will likely differ from much of the guidance that will emerge from Europe as opposed to the US, which has fewer fi nancial restrictions on recommendations.”
Self-citationEsketamine Nasal Spray versus Quetiapine for Resistant Depression
(2024) · New England Journal of Medicine · doi:10.1056/nejmc2313230 · Cited by 1
Efficacy of rTMS on SCZ symptoms: Insights from connectome mapping
Zhu, T., Jiao, X., Zhou, J., Nicholas, P. J., Osipowicz, K. Z., Doyen, S., Sughrue, M. E., Wang, Y., Zhang, Y., Zhu, J. J., et al. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116568 · Cited by 1
Samalin, L., Boudieu, L., & Llorca, P. (2025) · Neuromethods · doi:10.1007/978-1-0716-4599-4_14 · Cited by 1
Self-citationNMDA receptor kinetics drive distinct routes to chaotic firing in pyramidal neurons
Borjkhani, M., Borjkhani, H., Sharif, M. A., Bahrami, F., & Janahmadi, M. (2026) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2026.1753444 · Cited by 1
Clemens, K., Rive, B., Joshi, K., Thilakarathne, P. J., Kirson, N. Y., Desai, U. S., Doran, J., Eid, D., Qu, A., & Godinov, Y. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2555483 · Cited by 1
“While the primary end point of ESCAPE-TRD was remission at week 8 based on MADRS, the results of this measurement have previously been reported in the overall study population 13 and the US label subgroup 15,16 .”
InfluentialSelf-citationSmith, G., Piatkowski, T. M., Ferris, J., Bonenti, B., Davies, E., Barratt, M. J., Morgan, C. J. A., WINSTOCK, A. R., & Puljević, C. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251378509 · Cited by 1
“Overall, we found that more respondents experienced positive outcomes from therapeutic ketamine use than negative ones, aligning with existing evidence of ketamine’s efficacy as a rapid-acting antidepressant (Daly et al., 2019; Hopwood et al., 2024; Popova et al., 2019; Reif et al., 2023).”
Qutishat, M., Al‐Huseini, S., & Albalushi, M. (2026) · International Journal of Mental Health · doi:10.1080/00207411.2025.2610783 · Cited by 1
Gómez-Juanes, R., Lázaro, G. M., Castro, A., Navarra‐Ventura, G., Quetglas, J. A. M., Marset, A. B., Monasterio, J. V. D. W., Trullols, J. A. G., Roca, M., Gili, M., et al. (2026) · The European Journal of Psychiatry · doi:10.1016/j.ejpsy.2026.100349 · Cited by 1
“The tolerability profile aligns with results from randomized controlled trials; while serious adverse events remain rare, the frequency of transient hypertension and dissociation necessitates rigorous clinical monitoring 18-21 .”
Hejazi, M., Owen, X., Edwards, D. J., Hindle, M., Longest, P. W., Schuman, T. A., Walenga, R. L., Chopski, S. G., Kaviratna, A., Newman, B. W., et al. (2026) · Pharmaceutical Research · doi:10.1007/s11095-026-04066-8 · Cited by 2
García-Jiménez, J., Núñez-Arias, D., Merelo, G. C., Miller, A., Romero, A. M., Gutiérrez-Rojas, L., & Mesones-Peral, J. E. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261430495 · Cited by 1
“…studies, including ESCAPE-TRD, report progressive increases in response and remission rates beyond week 8, supporting the presence of “late improvers” and a temporal dissociation between early pharmacodynamic effects and later clinical consolidation (Molero et al., 2025; Reif et al., 2023).”
Psychostimulants for Depression in Serious Illness: Limited Evidence, Select Indications.
Sadowska, K., Chammas, D., Pattillo, M., McDermott, C., Ufere, N., Webb, J. A., & Shalev, D. (2026) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2026.03.015
Esketamine Nasal Spray: Mechanism of Action, Clinical, and Translational Science
van Hoogdalem, M. W., Fu, D., Drevets, W. C., & Zannikos, P. (2026) · Clinical and Translational Science · doi:10.1111/cts.70527 · Cited by 2
“…has been investigated in a broad clinical development program in TRD and MDSI, including early Phase 1 studies, key Phase 2 trials [42, 45], and large Phase 3 investigations, such as the long-term SUSTAIN-3 study [41] and the active-controlled (quetiapine extended release) ESCAPE-TRD trial [46].”
Self-citationThe value of innovation: Challenges and perspectives in mental health
Díaz‐Marsá, M. (2026) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.sjpmh.2026.03.003 · Cited by 1
An, J., Li, X., Li, Z., Wang, J., & Pan, Y. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04417-y · Cited by 5
“…Strategy (REMS) program—requiring supervised administration under healthcare professional supervision, use of two or three devices per dose with 5-min rest intervals between devices, and a minimum 2-h post-dose monitoring period—has effectively mitigated risks in real-world settings [22, 124].”
Cuomo, A., McIntyre, R. S., Koukouna, D., Pinzi, M., Pardossi, S., Firenzuoli, B., Barillà, G., Carmellini, P., Alamia, A., & Fagiolini, A. M. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261437597 · Cited by 1
Bayas, M., Auerbach, J., Diekamp, B., Fomenko, M., Baune, B. T., Repple, J., Reif, A., & Reif-Leonhard, C. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.112846 · Cited by 2
Self-citationPatient-centred education for ketamine and esketamine therapies in mood disorders
Kachlik, Z., Cubała, W. J., & Walaszek, M. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261456405 · Cited by 1
“These treatments are characterized by: • Rapid onset of action 7 ; • A distinctive profile of acute perceptual and dissociative effects 5 ; • Transient haemodynamic changes 5 ; • The need for specialized settings and staff 8 ; and • A non-trivial potential for misuse.”
Regen, F. (2026) · Springer eBooks · doi:10.1007/978-3-662-72452-1_1 · Cited by 1
Kynurenine pathway profiles as markers of ketamine response in treatment-resistant depression
Pedraz-Petrozzi, B., Marszałek‐Grabska, M., Fornal, E., Wielgosz, A., Stachniuk, A., Marzec, P., Neumann, E., Riedinger, E., Gilles, M., Gründer, G., et al. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106889 · Cited by 1
Westhoff, M. S., Toto, S., Bleich, S., Grohmann, R., & Seifert, J. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122322 · Cited by 1
Martiadis, V., Raffone, F., Atripaldi, D., Pessina, E., Cattaneo, C. I., Testa, S., Iaccarino, C., d’Andrea, G., Cavallotto, C., Olivola, M., et al. (2026) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-026-02361-4 · Cited by 1
Pompili, M., Sarubbi, S., Biase, G. D., Roberto, P., Fascetti, W., Trocchia, M. A., Erbuto, D., & Berardelli, I. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.09.005 · Cited by 1
Ketamin und Esketamin: Antidepressive pharmakologische Effekte und augmentierte Psychotherapie
Schüle, C., Koller, G., & Herwig, U. (2024) · Nervenheilkunde · doi:10.1055/a-2309-6457 · Cited by 1
García, J. M., Lasala, M. T. P., Trancón, M. B., Mellado, R. J. L., Caballero, A. J. U., Villalobos, R. F., & Baca, J. E. R. (2024) · Psiquiatría Biológica · doi:10.1016/j.psiq.2024.100547 · Cited by 1
Lv, X.-L., Liu, Q., Yu, J.-P., Cai, X., Wu, L., Yang, J., & Dong, Y. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s505020 · Cited by 2
“38,39 These findings indicates that”
InfluentialKennedy, K. P., Heldt, J. P., & Oslin, D. W. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002025 · Cited by 3
Esketamine for Treatment-Resistant Depression in Pakistan: A Promising Strategy
Memon, M., Gul, R., Gul, A., Bansari, S., Bansari, M., Khowaja, A., Kumar, S. G., Kumar, K., Khan, K. S., Iman, K., et al. (2025) · Hospital Pharmacy · doi:10.1177/00185787251384516 · Cited by 2
Gowthami, B., Mehta, I., Baiju, S., Appani, A., Suvarna, T., Randhawa, K., Kakkad, A. M., Syed, A. B., Kumar, V., Ramteke, H. D., et al. (2025) · medRxiv · doi:10.1101/2025.09.22.25336317 · Cited by 2
Loosening the Shackles of Depression
McShane, R. H. (2023) · New England Journal of Medicine · doi:10.1056/nejme2309758
Schwartz, T. L. (2023) · Global Journal of Medical Case Reports · doi:10.31586/gjmcr.2023.809
“Furthermore, patients in the esketamine group were 1.55 times as likely as patients in the quetiapine group to have no relapse through week 32 after remission at week 8 [17, 18].”
BackgroundInfluentialWunsch und Wirklichkeit bei der Depressionsbehandlung
Goerke-Arndt, F. (2023) · NeuroTransmitter · doi:10.1007/s15016-023-3306-4
Are ketamine and its enantiomers the answer to treatment-refractory depression?
Belge, J.-B., Scantamburlo, G., & Constant, E. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2373302
Research Progress of Esketamine in Improving Perioperative Depression and Sleep Quality
高, 永. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1472116
Anisman, H., Hayley, S. P., & Kusnecov, A. W. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23565-8.00006-5
(2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23565-8.09996-8
Gründer, G. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21199-7.00007-6
Клен, Е. Э., Никитина, И. Л., Халиуллин, Ф. А., et al. (2024) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-024-03265-0
Back, M. S., Santiago, P. R. B., & Pellin, G. M. (2025) · Revista Contemporânea · doi:10.56083/rcv5n2-072
Jha, M. K., Teeple, A., Shepherd, J., Gillespie, A., Grant, N., Mortimer, A., Kirkman, S., Middleton‐Dalby, C., & Joshi, K. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2463975
“Esketamine has shown high levels of efficaciousness in clinical trial settings, both in patients with TRD 12,39 and MDSI 40,41 .”
Busz, A., Schmidt, E. (. J. )., van den Brink, R., Foeken, K., de Jong, M., Mertens, J. (. B. C. )., van Noorden, M. S., Olivier, E. (. J. F. L. )., Schruers, K. R. J., Schutters, S. I. J., et al. (2025) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2025.100905 · Cited by 2
Biological mechanisms of stress-related mental disorders
Shi, D., Wang, L., Li, X., Hu, J., Qin, S., Zhao, M., Duan, S., Wang, Y., & Wang, Z. (2025) · Scientia Sinica Vitae · doi:10.1360/ssv-2024-0346
Cost-per-remitter for esketamine nasal spray versus quetiapine for treatment-resistant depression
Clemens, K., Teeple, A., Rive, B., Kirson, N. Y., Desai, U. S., Doran, J., Eid, D., Qu, A., Bowrey, H. E., & Joshi, K. (2025) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2024-0092
“In the ESCAPE-TRD trial, treatment with ESK NS + OAD resulted in higher response and remission rates compared with QTP XR + OAD among adults with TRD [13 , 17] .”
InfluentialSelf-citationEvaluation the inhibitory effect of nicardipine on the metabolism of quetiapine
Yang, J., Xia, H., Li, Q., Li, R., Cao, L., & Tang, C. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1567044
Ketamine toxicity: Translating preclinical findings to adverse effects in humans
Nezic, K., Ntafoulis, I., & Jacobs, G. E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29930-8.00009-6
立石, 洋., & 溝口, 義. (2024) · Kyushu Neuropsychiatry · doi:10.11642/kyushuneurop.70.1_3
Schillo, S., Schiweck, C., Aichholzer, M., Yotova, A. Y., Tsengenbayar, T., Thanarajah, S. E., Reif, A., & Freudenberg, F. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1576880
“Escalated treatment strategies such as antipsychotics, lithium, electroconvulsive therapy and, more recently, esketamine (4), can only partially address this treatment gap but are insuf fi cient for many patients.”
Self-citationIntranasal esketamine for depression: Transforming psychiatric treatment or a temporary solution?
Cartas, N., Dăscălescu, I., Neaga, A., Păun, M. L., & Petriuc, A. F. (2025) · Bulletin of Integrative Psychiatry · doi:10.36219/bpi.2025.3.07
Esketamine for Treatment-Resistant Depression—Reply
Janik, A., Shelton, R. C., & Fu, D. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.3248
Self-citationLupi, M., Carano, A., Acciavatti, T., Marini, S., Palmucci, M., Marinucci, E., Paolini, E., Gentile, A., Barioglio, A., Giri, M., et al. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002042 · Cited by 1
Zhu, X., Bao, W., Wang, L., Huang, L., Wang, Q., & Pan, L. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s579720 · Cited by 4
“11 Its neuroprotective 12 and antidepressant effects 13 may offer added benefit, particularly in patients with psychological risk factors for CPSP.”
da Silva, F. A., Avelar, R. S., Peixoto, B., Bacelar–Nicolau, L., Santos, F., Ribeiro, J. C., & Heitor, M. J. (2026) · Brain and Behavior · doi:10.1002/brb3.71164 · Cited by 1
“In 2023, Reif et al. published a study comparing the effect of eske-tamine with quetiapine when combined with an SSRI or SNRI in resistant depression, showing better results with esketamine (Reif et al. 2023 ).”
Eckert, D., & Kasper, S. F. (2026) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2026.2617195 · Cited by 3
Yoon, S. (2026) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/ceog45609
Mechanism of action of REDD1 in depression and its targeted intervention
Guan, W., Meng, Y.-T., & Miao, Y. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117878 · Cited by 1
Effects of esketamine combined with QLB in older frail patients with colorectal cancer surgery
Dai, S., Wang, L. Y., Zhang, K., Wang, R., Li, N., & Zhang, X. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1749820
“The addition of esketamine, known for its rapid onset and short duration of action, further enhances recovery by reducing the time patients spend under the influence of anesthetics (30).”
Samalin, L., Arnoud, A., Ducher, L., Charpeaud, T., Jabaudon-Gandet, M., & Llorca, P. (2026) · Encyclopédie médico-chirurgicale. Psychiatrie · doi:10.1016/s0246-1072(25)48449-1
Self-citationKetamine in clinical psychiatry and addictology - a narrative review
Vašíček, O., & Páleníček, T. (2026) · Psychiatrie pro praxi · doi:10.36290/psy.2026.004
Psychedelics: Future Therapeutics in Major Depression?
Olivier, B., & Olivier, J. D. A. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-981-95-6872-7_25
Eckert, D., & Kasper, S. F. (2026) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2026.2663307
Ding, X., Hashimoto, K., & Yang, J.-J. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111727
Walters, C. K., Chetty, S., Rants’o, T. A., Gossayn, S., & Lerotholi, L. J. (2026) · Research Square · doi:10.21203/rs.3.rs-9283280/v1
Pharmacological augmentation for people with treatment-resistant depression
Strawbridge, R., Nikolova, V. L., Browning, M. D., Rucker, J., Cowen, P. J., Cousins, D. A., Young, A. H., & Cleare, A. J. (2026) · The British Journal of Psychiatry · doi:10.1192/bjp.2026.10673
Self-citationMartínez‐Gras, I., Molina, J. D. D., Sánchez-Pastor, L., Llamas, S., Espejo-Saavedra, J. M., Compaired, A., Leza, J. C., & Rubio, G. (2026) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2026.100332
Bu, F., Qin, L., Zi-yang, L. O. U., Xie, Y., Zhang, S. Z., Xiong, L., & Wen, Y. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s609327
“14,15 These features do not negate its value, but they do mean that its place in care is selective rather than universal.”
Qu, Y., Li, S., Tian, L., Tian, X., & Wu, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1792570 · Cited by 1
“…recent systematic reviews and meta-analyses have evaluated the general safety and efficacy of esketamine (Liu et al., 2022; Nikolin et al., 2023; Reif et al., 2023; Rodolico et al., 2024; Seshadri et al., 2024; Guo et al., 2025), yet it is associated with transient adverse events (AEs) such as…”
API synthesis in continuous flow
Cots, E., Alza, E., Diéguez, M., & Pericàs, M. À. (2026) · Advances in catalysis · doi:10.1016/bs.acat.2026.04.002
Revisiting the Management of Treatment-Resistant Depression
Lee, J. J., & Blumberger, D. M. (2026) · The Canadian Journal of Psychiatry · doi:10.1177/07067437261456022
“10 In direct head-to-head trials, esketamine has demonstrated superiority over standard augmentation strategies in both acute and long-term outcomes, 11 establishing it as a potent alternative for patients failing standard augmentation strategies.”
Varela, Y. M., Ribeiro, P. C., de Sousa, G. M., Falchi-Carvalho, M., Barbalho, J. D. S. F., Gomes, R. B. D. O., Gurgel, M. M. M., Pereira, B. C., Souza, P. M. D. L., Gonçalves, K. T. D. C., et al. (2026) · medRxiv · doi:10.64898/2026.05.31.26354555
Bonnet, U., Scherbaum, N., Juckel, G., & Bschor, T. (2026) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2846-4275 · Cited by 1
Yang, X., Gao, T. Y., Wang, S. Y., Hu, L., Huang, F., Cui, W., & Zhang, L. (2026) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2026.112246 · Cited by 1
El impacto de esketamina intranasal en la depresión resistente: 5 años de datos clínicos
González-Pinto, A. (2026) · Psiquiatría Biológica · doi:10.1016/j.psiq.2026.100931
Westenhöfer, S., Ehrt‐Schäfer, Y., Provaznikova, B., Prinz, S., Spies, M., Akhmetova, L., Nadesalingam, N., Strickler, E., Krähenmann, R., Seifritz, E., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10250654/v1
Bellanti, P. A., Lewis, J., Seifferth, B., & Adams, D. Z. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1867963 · Cited by 2
“Randomized clinical trials have repeatedly demonstrated that intranasal esketamine produces meaningful reduction in depressive symptoms for patients with TRD compared to standard therapies alone (9, 10).”
The Gut–Brain Axis in Ganoderma lucidum’s Antidepressant Effects in Cancer Comorbidity: A Review
Du, X.-Y., Bu, F., & Ling, Z. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101731
Young, A. H., Baune, B. T., Benatti, B., Bennabi, D., Estercam, S., Gorwood, P. A. P. M., Gutiérrez-Rojas, L., Martiadis, V., Molero, P., Normann, C., et al. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.112907 · Cited by 1
Self-citationGu, T., Zhang, J., Wang, R., Guo, F., Shu, W., Ouyang, Q., He, R., Zhang, T., Zheng, Q., Sun, L., et al. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122307
d'Andrea, G., Cavallotto, C., Susini, O., Marsico, F., Mammarella, G., Tamagnini, G., Inserra, A., Mancusi, G., di Lorenzo, G., Barlattani, T., et al. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122333
THE IMPACT OF INTRANASAL ESKETAMINE ON TREATMENT-RESISTANT DEPRESSION: A SYSTEMATIC REVIEW
Kotlarski, W., Kotlarska, K. M., Mainka, T. S., & Sergejuk, E. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5523
Metadata
- Authors
- Reif, A., Bitter, I., Buyze, J., Cebulla, K., Frey, R., Fu, D.-J., Ito, T., Kambarov, Y., Llorca, P.-M., Oliveira-Maia, A. J., Messer, T., Mulhern-Haughey, S., Rive, B., von Holt, C., Young, A. H., & Godinov, Y.
- Affiliations
- Semmelweis University (HU)
- From the Department of Psychiatry, Psychosomatic Medicine, and Psychotherapy, University Hospital, Goethe University Frankfurt, and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt (A.R.), Danuvius Klinik, Technische Universität München, Pfaffenhofen an der Ilm (T.M.), and Janssen Germany (K.C.) and Janssen EMEA (C.H.), Neuss — all in Germany; the Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary (I.B.); Janssen Pharmaceutica (J.B.) and Janssen EMEA (Y.K.) — both in Beerse, Belgium; the Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna (R.F.); Janssen Research and Development, New Jersey (D.-J.F.); Janssen EMEA, High Wycombe (T.I.), the Department of Psychological Medicine, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, and South London and Maudsley NHS Foundation Trust, Bethlem Royal Hospital, Beckenham (A.H.Y.) — all in the United Kingdom; CHU Clermont-Ferrand, Departme...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-10-05
- Volume
- 389
- Issue
- 14
- Pages
- 1298-1309
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4387324672
- Cited by
- 222
- References
- 29
- Citations by year
- 2026: 76 · 2025: 80 · 2024: 58 · 2023: 8
- FWCI
- 34.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Janssen EMEA
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- esketamine, quetiapine, treatment-resistant depression, augmentation therapy, remission, relapse prevention, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, antidepressant efficacy, adverse events, NMDA receptor antagonists, ketamine, atypical antipsychotics, Montgomery-Asberg Depression Rating Scale, treatment response
- MeSH terms
- Serotonin and Noradrenaline Reuptake Inhibitors, Quetiapine Fumarate, Antidepressive Agents, Delayed-Action Preparations, Depression, Drug Therapy, Combination, Humans, Ketamine, Recurrence, Single-Blind Method, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Nasal Sprays, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.